Stock Price
29.05
Daily Change
-2.39%
Yearly
-42.18%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Astellas Pharma 1,916.00 -8.50 -0.44% 21.27%
Agios Pharmaceuticals 36.45 -0.80 -2.15% -18.40%
Alnylam Pharmaceuticals 188.53 -0.27 -0.14% 45.18%
Arena Pharmaceuticals 57.42 -1.54 -2.61% -12.87%
Arrowhead Research 72.02 -2.02 -2.73% 14.34%
BioCryst Pharmaceuticals 12.48 -0.02 -0.16% 143.27%
Bluebird Bio 10.50 -0.26 -2.42% -76.17%
BioMarin Pharmaceutical 87.58 -1.99 -2.22% 8.93%
Dicerna Pharmaceuticals 37.99 -0.01 -0.03% 54.81%
Esperion Therapeutics 7.78 0.09 1.17% -71.21%
Exelixis 17.06 -0.42 -2.40% -12.11%
GW Pharmaceuticals 218.96 0 0% 108.53%
Halozyme Therapeutics 33.85 -1.42 -4.03% -15.86%
Intercept Pharmaceuticals 17.10 -0.65 -3.66% -54.12%
Moderna Inc 329.63 56.24 20.57% 159.49%
Mirati Therapeutics 136.76 -4.44 -3.14% -41.19%
Neurocrine Biosciences 86.98 -0.88 -1.00% -8.98%
Nektar Therapeutics 11.21 -0.41 -3.53% -33.23%
Novartis 74.72 -1.85 -2.42% -7.82%
Omeros 7.43 -0.37 -4.74% -36.71%
Pfizer 54.00 3.11 6.11% 45.04%
PTC Therapeutics 38.06 -1.35 -3.43% -40.52%
Ultragenyx Pharmaceutical 76.49 -1.09 -1.41% -37.52%
Regeneron Pharmaceuticals 643.35 -4.83 -0.75% 25.15%
Roche Holding 358.60 -3.45 -0.95% 18.55%
Sarepta Therapeutics 79.62 -1.36 -1.68% -42.78%
Vertex Pharmaceuticals 183.59 -2.65 -1.42% -19.02%


Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company is primarily focused on two core franchises: neurology and cardiometabolic. Its products include SPINRAZA, TEGSEDI and WAYLIVRA. SPINRAZA is for treatment of patients of all ages with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. TEGSEDI is for the treatment of patients with polyneuropathy caused by hereditary transthyretin (TTR), amyloidosis (hATTR), a debilitating, progressive, and fatal disease. Its products in pipeline include tofersen for SOD1-ALS, eplontersen (IONIS-TTR-LRX) for TTR, IONIS-APOCIII-LRx for familial chylomicronemia syndrome (FCS), pelacarsen for lipoprotein(a) (Lp), driven cardiovascular disease and ION363 for amyotrophic lateral sclerosis (ALS), with mutations in the fused in sarcoma gene (FUS).